Variations in time of market exclusivity among top-selling prescription drugs in the United States

JAMA Internal Medicine

Volumn 175, Issue 4, 2015, Pages 635-637

  Wang, Bo ^a   Liu, Jun ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CARDIOVASCULAR AGENT; DERMATOLOGICAL AGENT; GENERIC DRUG; PRESCRIPTION DRUG;

ARTICLE; DRUG APPROVAL; DRUG FORMULATION; DRUG MARKETING; ENDOCRINOLOGY; FOOD AND DRUG ADMINISTRATION; HEMATOLOGY; HUMAN; LAW; METABOLITE; ONCOLOGY; PATENT; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; RESOURCE ALLOCATION; UNITED STATES; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; HEALTH CARE COST; TIME;

DRUG APPROVAL; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH CARE SECTOR; HUMANS; PATENTS AS TOPIC; PRESCRIPTION DRUGS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84923894594     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.7968     Document Type: Article

References (7)

1. Amin T, Kesselheim AS. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Aff (Millwood). 2012;31(10):2286-2294.
2. Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Aff (Millwood). 2011;30(11):2157-2166.
3. Centers for Medicare & Medicaid Services. Medicaid drug programs data & resources. http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Programs-Data-and-Resources.html. Accessed April 13, 2014.
4. Food and Drug Administration. Drugs@FDA: FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed April 13, 2014.
5. Kesselheim AS, Darrow JJ. Drug development and FDA approval, 1938-2013. N Engl J Med. 2014;370(26):e39.
6. Lanthier M, Miller KL, Nardinelli C, Woodcock J. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood). 2013;32(8):1433-1439.
7. HR 3590, 111th Cong, §7002 (2011).